(Q34409544)

2 August 2017

1 reference

title

The use of gabapentin enacarbil in the treatment of restless legs syndrome (English)

1 reference

2 August 2017

main subject

restless legs syndrome

0 references

gabapentin

0 references

gabapentin enacarbil

1 reference

ChEBI release 2020-05-28

Toby C Yaltho

1

1 reference

2 August 2017

William G Ondo

series ordinal

2

1 reference

2 August 2017

publication date

1 September 2010

1 reference

Therapeutic advances in neurological disorders

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

269-275

1 reference

A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Restless legs syndrome prevalence and impact: REST general population study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Restless legs syndrome: clinicoetiologic correlates

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Restless legs syndrome and sleep bruxism: prevalence and association among Canadians.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Restless legs syndrome improved by pramipexole: a double-blind randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Epidemiology of restless legs symptoms in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610378059

Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002665

27 October 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21179617

12 December 2020

inferred from PubMed ID database lookup

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21179617

12 December 2020

inferred from PubMed ID database lookup

Restless legs syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21179617

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1177/1756285610378059

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7tindd7dsnbxvdxxzadexzmh24

30 July 2022

release_7tindd7dsnbxvdxxzadexzmh24

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7tindd7dsnbxvdxxzadexzmh24

30 July 2022

https://api.fatcat.wiki/v0/release/7tindd7dsnbxvdxxzadexzmh24

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/7tindd7dsnbxvdxxzadexzmh24

1 reference

30 July 2022